Atezolizumab Immunotherapy With or Without Tiragolumab for Patients With Unresectable Stage III NSCLC
Study Information
Alliance Study ID: AFT-57
NCT Study ID (ClinicalTrials.gov): NCT05798663
Alliance Committee: Respiratory Cancer
Disease or Cancer Type: Lung Cancer & Mesothelioma
Alliance Study Chair: Helen Ross, MD
Status: ACTIVE_NOT_RECRUITING
Study Description
This is a phase II trial of neoadjuvant and adjuvant atezolizumab with or without tiragolumab in conjunction with chemoradiotherapy for unresectable stage III NSCLC.
Related Publications
For publications related to this and other clinical trials, visit the Alliance Publications Application.
Locations (15)
University of California San Diego Moores Cancer Center
La Jolla, California 92037
United States
Kaiser Permanente Oakland Medical Center
Oakland, California 94611
United States
Kaiser Permanente Roseville Medical Center
Roseville, California 95661
United States
Kaiser Permanente San Francisco Medical Center
San Francisco, California 94115
United States
Kaiser Permanente Santa Clara Medical Center
Santa Clara, California 95051
United States
Kaiser Permanente Vallejo Medical Center
Vallejo, California 94589
United States
Rush University Medical Center
Chicago, Illinois 60612
United States
Washington University Siteman Cancer Center
St Louis, Missouri 63110
United States
Missouri Baptist Medical Center
St Louis, Missouri 63131
United States
University of Nebraska Medical Center
Omaha, Nebraska 68198
United States
New Hampshire Oncology – Hematology, PA
Manchester, New Hampshire 03103
United States
Hematology Oncology Associates of Central New York, P.C.
East Syracuse, New York 13057
United States
SUNY Upstate Medical University
Syracuse, New York 13210
United States
Ohio State University
Columbus, Ohio 43210
United States
University of Wisconsin
Madison, Wisconsin 53792
United States
Data Sources & Contacts
Full trial details
For more Information